Abstract
Introduction
Ovarian cancer poses a major health problem in women worldwide and is the fourth leading cause of cancer death in women in the United States [1] . The 5-year survival rate for early-stage patients is 80-90%, but only 25% for those diagnosed at advanced stages of the disease [2] . Unfortunately, most ovarian cancer patients have advanced disease at diagnosis [2] . Although the ovarian cancer mortality rate has not changed significantly during the past few decades, the length of survival for patients has been steadily improving, largely as a result of clinical applications of newer and more effective chemotherapeutic drugs for adjuvant therapy after surgery [2, 3] . [4] . Its major mechanism involves the formation of DNA adducts, resulting in G2 phase cell cycle arrest, subsequently triggering apoptosis. While effective, CBP induces side effects, including neurotoxicity and nephrotoxicity [5] [6] [7] . Therefore, it is necessary to develop novel drugs that can be used alone or in combination with conventional agents to overcome acquired drug resistance or sensitize tumours to therapy. (Fig. 1) , have been used in the clinic for many years [8] [9] [10] , and have recently been suggested to have anticancer effects [9, [11] [12] [13] [14] [15] [16] [17] [18] [19] . The mechanisms of action for their antitumour activities are not fully understood, but may include selective cytotoxicity of cancer cells [9, 13] , induction of apoptosis [20] [21] [22] [23] , modulation of gene expression [22, [24] [25] [26] [27] [28] , causation of cell cycle arrest [23, [29] [30] [31] and inhibition of angiogenesis [17, 23, 28, [32] [33] [34] . 
For instance, carboplatin (CBP) is one of the most important chemotherapeutic drugs used for adjuvant treatment of primary ovarian cancer and for metastatic disease

Artemisinin (ARS), a sesquiterpene lactone anti-malarial drug, and its analogues, including dihydroartemisinin (DHA), artesunate (ART) and artemether (ARM)
Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy
Cell viability assay
Cell growth and viability were determined via the MTT assay as described [35] [36] [37] [35] [36] [37] . figure) were combined. 
Detection of apoptosis
Mitochondrial membrane potential (⌬m) quantitation
Protein immunoblotting analysis
Immunoblotting was accomplished as described previously [37] [38] [39] [40] . 
Fig. 1 DHA selectively decreases cell viability and inhibits the growth of human ovarian carcinoma cells, but not non-tumourigenic ovarian surface epithelial cells. (A) Chemical structures of the four artemisinin (ARS) compounds; (B) Viability of human ovarian carcinoma cells (ovarian carcinoma A2780 and OVCAR-3) and non-tumourigenic OSE cells (IOSE144) after 48 hrs exposure to the ARS compounds as determined by MTT assay; C, Cell growth inhibi
DHA-induced apoptosis is associated with disruption of the mitochondrial membrane and release of cytochome c
After exposure to different concentrations of DHA, we evaluated the integrity and potential of the mitochondrial membrane in the A2780 (Fig. 4A ) and OVCAR-3 (Fig. 4B) 
cells. These figures demonstrate that exposure to DHA for 24 hrs resulted in a dose-dependent dissipation in potential (from 5 to 50 M) in both A2780 and OVCAR-3 cells, which was indicated by decreased ratios of red/green fluorescence intensity (Fig. 4A and B, P Ͻ 0.05). We also examined mitochondrial cytochrome c levels after exposure to the compound, and found a dose-dependent reduction in mitochondrial cytochrome c (Fig. 4C), which is in consistent with the activation of Bid by caspase-8 (Fig. 3). This suggests that DHA caused the release of cytochrome c from the mitochondria to the cytosol. Together, these results provide evidence that the DHA-induced apoptosis likely occurs through the mitochondrial pathway.
DHA increases the effectiveness of CBP in ovarian cancer cells through an increase in apoptosis
Since combination therapy is a major clinical approach to treatment, we investigated the effects of combining DHA with CBP, an agent commonly used to treat ovarian cancer [4] . As shown in Fig. 5A (Fig. 5D, P Ͻ 0.05) . A longer exposure to the compound may produce more dramatic effects on apoptosis.
DHA inhibits tumour growth, induces apoptosis and improves CBP therapy in vivo
We established A2780 and OVCAR-3 tumour xenograft models to determine whether DHA can exert antitumour effects in vivo. DHA was administered 5 days a week to mice in the treatment groups. Fig. 6A1 (Fig. 6B1, P Ͻ Fig. 6A2 and 6B2) , only mice receiving CBP treatment experienced slight weight loss. No other host toxicities were observed.
CBP was given once on day 0 at a single dose of 120 mg/kg. Therapeutic effects were evaluated by examining tumour growth. As shown in
0.05). In the CBPonly group, tumour growth was inhibited by 56% (A2780) and 46% (OVCAR-3) (Fig. 6A1 and 6B1, P Ͻ 0.05). Combining the two compounds (25 mg/kg DHA) led to 70% tumour growth inhibition in both the A2780 and OVCAR-3 models (P Ͻ 0.05). Moreover, based on observation of body weight (
As further validation of the mechanism by which DHA exerts its effects, we assessed the in vivo expression of some of the key apoptosis-related proteins mentioned above (Fig. 6C) . Consistent with the in vitro findings, we observed a dose-dependent decease in the Bcl-2/Bax ratio and a decrease in pro-caspase-8, confirming that DHA appears to exert its effect at least partly by causing apoptosis through the death receptor-and mitochondrion-mediated pathway.
Discussion
To our knowledge, this is the first published report systematically demonstrating that DHA exhibits significant in vitro and in vivo anticancer activities by inducing apoptosis through the death [9, 12, 14, 15, 42, 43] , limited studies have examined the effects on ovarian cancer [27, 44] . DHA-induced apoptosis was reported to occur through the caspase cascade [21] or via modulation of the Bcl-2 family [44] . DHA has also been shown to regulate angiogenesis-related genes [17, 22, 27, 28, 33] and cause cell cycle arrest [44] [45] . Members of the Bcl-2 family are known regulators of apoptosis [45, 46] Ovarian cancer is the most lethal malignant gynaecological disease worldwide [1, 2] . The acquired drug resistance of tumour cells and cumulative side effects of the cytotoxic agent present serious clinical obstacles [7] . Resistance and evasion of apoptosis are critical factors that contribute to carcinogenesis and drug resistance [46, 47] (Fig. 7A) , and indicates the possible mechanism by which DHA enhances the therapeutic effects of CBP (Fig. 7B) 
